

Are your MRI contrast agents cost-effective?

Learn more about generic Gadolinium-Based Contrast Agents.



**AJNR**

**Fluorodeoxyglucose–Positron-Emission  
Tomography Imaging of Head and Neck  
Squamous Cell Cancer**

R.M. Subramaniam, M. Truong, P. Peller, O. Sakai and G. Mercier

This information is current as  
of April 19, 2024.

*AJNR Am J Neuroradiol* 2010, 31 (4) 598-604

doi: <https://doi.org/10.3174/ajnr.A1760>

<http://www.ajnr.org/content/31/4/598>

# Fluorodeoxyglucose–Positron-Emission Tomography Imaging of Head and Neck Squamous Cell Cancer

## REVIEW ARTICLE

R.M. Subramaniam  
M. Truong  
P. Peller  
O. Sakai  
G. Mercier



**SUMMARY:** The hybrid technique of PET/CT has significantly impacted the imaging and management of HNSCC since its introduction in 2001 and has become the technique of choice for imaging of this cancer. Diagnostic FDG-PET/CT is useful for identification of an unknown primary tumor, delineation of extent of primary tumor, detection of regional lymph node involvement even in a normal-sized node, detection of distant metastases and occasional synchronous primary tumor, assessment of therapy response, and long-term surveillance for recurrence and metastases. The role of PET/CT is evolving in radiation therapy planning. Combined diagnostic PET/CT provides the best anatomic and metabolic in vivo information for the comprehensive management of HNSCC.

**ABBREVIATIONS:** CR = complete response; DCT = contrast enhanced diagnostic CT;  $^{18}\text{F}$  = fluorine-18; FDG = fluorodeoxyglucose; FDG-PET = fluorodeoxyglucose–positron-emission tomography; FNA = fine-needle aspiration; GTV = gross tumor volume; HNSCC = head and neck squamous cell carcinomas; IMRT = intensity modulated radiation therapy; M = metastasis; N = node; PET = positron-emission tomography; PTV = planning target volume; RD = residual disease; SCC = squamous cell carcinoma; SUV = standard uptake value;  $\text{SUV}_{\text{max}}$  = maximum SUV; T = tumor

More than 40,000 people are diagnosed with head and neck cancer each year in the United States.<sup>1</sup> The overall annual mortality rate for this cancer in the United States is 23%, and the 5-year survival rate is 56%.<sup>1-3</sup> More than 80% of early-stage tumors are cured, but nearly one-half of patients have evidence of advanced local disease or lymph node metastases at the time of diagnosis. Surgery and radiation therapy, either alone or in combination with chemotherapy, are used for definitive locoregional treatment of head and neck cancers. For patients with advanced-stage and high-risk features, postoperative chemoradiation improves locoregional control and overall survival.<sup>4,5</sup>

Cross-sectional imaging with CT and MR imaging is commonly used for tumor staging and may allow detection of subcentimeter lesions. Locoregional lymph node metastases have a major impact on survival. Patients with lymph-node involvement have a worse prognosis (approximately 30%) than patients without lymph node involvement (>50% 5-year survival).<sup>6,7</sup> PET using the radiotracer  $^{18}\text{F}$  FDG is widely used to evaluate patients with HNSCC. The hybrid technique, PET/CT, provides anatomic and functional information and can be performed as PET and DCT with intravenous contrast-enhancement (PET/DCT) or PET and noncontrast CT (PET/CT) for attenuation correction and anatomic localization. PET/CT is useful for identification of an unknown primary tumor, delineation of the extent of regional lymph node involvement, detection of distant metastases and occasional synchronous primary tumor, radiation-ther-

apy planning, assessing therapy response, and long-term surveillance for recurrence and metastases.

### PET/CT Protocols

PET/CT imaging was developed to improve PET imaging by expediting attenuation correction and improving lesion localization.<sup>8</sup> Hence, initial protocols for PET/CT imaging were designed to optimize the acquisition of the PET scan at the expense of the CT scan. For head and neck imaging, this meant that no intravenous contrast was used; a low-dose CT technique was common; and CT scans were reconstructed with a section thickness to match the PET scan (approximately 3–5 mm). Commonly, the imaging report emphasized the FDG-PET findings with CT findings described only if they were related to PET findings, were significant, or were obvious. The advantage of this approach is its simplicity and shorter time. The limitation is that most patients will need high-quality anatomic imaging for surgical planning, and this often requires a separate visit.

With experience and improvement in technology, it is now possible to acquire a high-quality DCT scan for surgical planning and PET for metabolic imaging at the time of PET/CT imaging.<sup>9</sup> This examination is referred to as PET/DCT-neck.<sup>10</sup> The advantage of this study is to perform a comprehensive evaluation of patients with HNSCC in a single visit to the imaging department. The addition of a diagnostic-level CT scan to FDG-PET scanning affords hardware fusion of the images and the opportunity for a single report to incorporate results from both imaging studies. In general, nodal status and distant metastases are best evaluated by the PET component of the examination, but the morphology and relation of the primary lesion to critical anatomic structures are best evaluated by the CT component of the examination. The trade-off is an examination that takes longer to perform and interpret and requires technical and interpretive expertise in PET and CT modalities.


From the Departments of Radiology (R.M.S., O.S., G.M.) and Radiation Oncology (M.T.), Boston Medical Center and Boston University, Boston, Massachusetts; and Department of Radiology (P.P.), Mayo Clinic, Rochester, Minnesota.

Please address correspondence to Rathan Subramaniam, MD, Divisions of Neuroradiology and Molecular Imaging, Department of Radiology, Boston University Medical Center, 820 Harrison Ave, Boston MA 02118; e-mail: rathan.subramaniam@bmc.org




Indicates open access to non-subscribers at [www.ajnr.org](http://www.ajnr.org)

DOI 10.3174/ajnr.A1760



**Fig 1.** Surgical planning and metabolic staging. A 50-year-old man with T4N2bM0 SCC of the right tonsil and base of the tongue. The contrast-enhanced CT component of the PET/DCT provides the high-resolution imaging necessary for surgical planning (red arrows), with the tumor involving the right tonsil and tongue base. The PET component of the PET/DCT provides the metabolic information about the primary tumor and locoregional and distant metastatic disease. The patient underwent resection with pectoralis flap reconstruction and concurrent chemoradiation. *A and B*, Contrast-enhanced CT of PET/CT. *C–E*, Fused PET/CT images. FDG uptake provides the primary tumor and metastatic lymph node metabolism (yellow arrows).



**Fig 2.** Detection of unknown primary tumor. A 58-year-old man who presented with a right neck mass. A neck CT shows multiple enlarged necrotic right level II, III, and IV lymph nodes. FNA of the right level III node showed a metastatic poorly differentiated carcinoma with extensive necrosis. PET/CT showed a  $1.0 \times 1.2$  cm hypermetabolic (gold arrow) and enhancing (red arrow) lesion at the right base of the tongue, large nodes in the right levels II/III, an 8-mm node at level IV, and no left-sided nodes or distant metastases. Direct laryngoscopy with biopsy and cervical esophagoscopy showed no lesions, but palpation showed a 1-cm firm right base of tongue lesion not crossing the midline, which was pathologically proved to be SCC. PET/CT is useful in identifying the unknown primary tumor in approximately one-third of patients after physical examination, anatomic cross-sectional imaging, and endoscopy. *A–C*, Fused PET/CT images. *D–F*, Contrast-enhanced CT of the PET/CT.


At our institution, the head and neck surgeons have gravitated from the routine PET/CT to the more comprehensive PET/DCT. It not only images the neck with a diagnostic-quality CT scan but also includes the chest, abdomen, and pelvis to complete a CT scanning that matches a PET scanning from the skull base to the midhigh, providing both metabolic and high-quality anatomic imaging, the workhorse of oncology imaging. This examination provides a 1-stop shopping experience that simplifies scheduling, allows staging and surgical planning at the same time (Fig 1), and is convenient for the patient. A single report is provided by an attending radiologist who has expertise in both PET and CT modalities.

The PET/DCT is performed in 2 parts. A dedicated PET/DCT for the neck is performed with the arms down and thinner CT sections (1.25 cm), by using a 256 PET matrix and 60 mL of noniodinated intravenous contrast agent. It covers from the skull base to the arch of the aorta, including the nodal


chains draining the head and neck. The second part of the PET/DCT study covers from just above the clavicles to the midhigh with 100 mL of noniodinated intravenous contrast agent.

### Detection of Unknown Primary Tumor

In approximately 5%–10% of the patients with head and neck tumors presenting with a neck mass, the primary tumor cannot be identified by physical examination, panendoscopy, and anatomic imaging such as CT or MR imaging. The most common sites for occult primary HNSCC are the tonsillar fossa, the nasopharynx, the base of the tongue, and the pyriform sinus. FDG-PET has proved to be a complementary study for patients with unknown primary tumor of the head and neck when conventional evaluation fails (Fig 2).<sup>11–18</sup> A review of 16 studies published between 1994 and 2003 evaluating the utility of FDG-PET in identifying unknown primary carcinomas af-



**Fig 3.** Failure to detect an unknown primary tumor. A 50-year-old man who underwent a dental extraction in which the oral surgeon incidentally identified a right-sided neck mass that was tender to touch. FNA revealed moderate to poorly differentiated SCC. PET/DCT demonstrates FDG hypermetabolic (*gold arrow*) and enhancing (*red arrow*) lymphadenopathy in the right levels I-III and fails to reveal a primary lesion. Same-day rigid esophagoscopy, direct laryngoscopy, nasal endoscopy with biopsy of the base of the tongue bilaterally, and tonsillectomy showed no tumor. The patient was treated in all potential mucosal primary sites and the bilateral neck with IMRT to a dose of 69.96 Gy in 33 fractions with concurrent cisplatin. A, C, and D, Fused PET/CT images. B, Contrast-enhanced CT of the PET/CT.



**Fig 4.** Perineural spread. A 65-year-old woman diagnosed with T4N0M0 SCC of the skin of the left upper lip and perineural spread along infraorbital nerve and VI to the skull base. PET/DCT demonstrates a hypermetabolic and enhancing mass in the left upper lip extending along the infraorbital nerve and at the skull base (*gold arrows*). MR imaging demonstrates these findings (*red arrows*) with higher resolution. The perineural spread is better depicted on the MR imaging than PET/CT due to higher resolution and small-volume disease along the nerve. A, B, and D, PET/DCT fused images. C, Contrast-enhanced coronal CT scan. E and G, Coronal T1 pregadolinium images. F and H, Postgadolinium coronal T1 images.

ter negative findings on conventional work-up showed that FDG-PET detected the primary tumor in 74 of 302 patients (24.5%). PET/CT failed to detect the unknown primary tumor in approximately 65%–75% of cases (Fig 3). The overall PET sensitivity was 88%; specificity, 75%; and accuracy, 79%. When the performance by FDG-PET was evaluated by anatomic site, a lower sensitivity for base of tongue cancers and a lower specificity for tonsillar cancers were observed.<sup>15</sup>

The limitation of PET/CT in identifying unknown primary cancers in the head and neck is due to the resolution of FDG-PET, which is limited to approximately 5 mm. Small or superficial lesions may be undetected. The basal uptake of FDG in the normal lymphoid tissues of the Waldeyer ring and the secretion of FDG from salivary glands would further obscure detection of small and superficial lesions.

## Staging

### T Stage


Accurate assessment of the primary tumor depends on the extent of the lesion and involvement of adjacent structures. Contrast-enhanced CT or MR imaging provides complementary information to physical examination and endoscopy and has become essential for primary-tumor assessment. MR imaging provides superior soft-tissue delineation and better assessment of perineural (Fig 4) and bone marrow extension of the primary tumor. Although PET is highly accurate in the detection of primary tumor,<sup>19,20</sup> the resolution is inferior to CT and MR imaging in depicting the anatomic detail and the extent of the tumor that is essential for surgical planning. PET

and PET/CT without contrast do not provide the anatomic detail sufficient for surgical planning purposes. PET/DCT provides the best combination of anatomic detail that is sufficient for surgical planning purposes and functional characteristics of a primary lesion.


### N Stage

Nodal spread is the most important prognostic factor in the management of all patients with head and neck cancer except those with thyroid cancer. The presence of metastatic lymph nodes in the ipsilateral or contralateral side of the neck or both significantly reduces the 5-year disease-specific survival rate in patients with HNSCC.<sup>21</sup> The number of involved nodes, location, and evidence for extracapsular spread determine treatment and prognosis. CT and MR imaging are the preferred anatomic modalities to image metastatic nodes. CT is superior to MR imaging in diagnosing the metastatic nodes in the head and neck.<sup>22</sup> One of the hallmarks of the metastatic node is increase in size. On the basis of pathologic findings, a minimum axial diameter of 10 mm was the most effective size criterion, while the best size criterion was 1–2 mm greater for the nodes at levels IB and II.<sup>23,24</sup> However, smaller (<10 mm) nodes can harbor metastasis that could be imaged by metabolic imaging.

FDG-PET is often superior to conventional anatomic imaging in detecting regional nodal metastasis at the initial staging of patients with HNSCC.<sup>25,26</sup> PET is particularly useful in identifying metastatic nodes <10 mm that appear morphologically normal but are FDG-avid (Fig 5) or those in locations difficult to image with CT, such as supraclavicular nodes. In a



**Fig 5.** Staging. A 62-year-old man with a stage IVa (T2 N2cM0) SCC of the tongue with a central necrotic right IB (red arrow) and right IIA (yellow arrow) FDG hypermetabolic lymphadenopathy. The left IIA lymph node (<10 mm) demonstrates FDG hypermetabolism, proved pathologically to be metastatic. Even smaller lymph nodes with apparent mild FDG uptake due to partial volume may harbor metastatic deposits.



**Fig 6.** Radiation therapy planning. A, Planning CT GTV in red and PTV in blue. Green and aqua contours represent elective nodal volumes. B, PET. C, Rigid fusion of planning CT and PET for radiation planning. The PET/CT scan was obtained in the treatment position with rigid immobilization in a thermoplastic head and neck mask.

review, an average sensitivity of 87%–90% and a specificity of 80%–93% were reported for FDG-PET.<sup>27</sup> Recent advances in technology would improve the sensitivity, and hybrid PET/DCT would improve the specificity of metastatic nodal detection.

The SUV of reactive nodes may overlap that of malignant nodes, though malignant nodes tend to have significantly higher SUV in the untreated patient.<sup>28</sup> The SUV cutoff values for malignant nodes can vary depending on the size of the nodes. In a recent study of 23 patients, 19 positive and 93 negative nodal levels were identified. The SUV<sub>max</sub> overlapped in negative and positive nodes <15 mm in diameter. According to receiver operating characteristic analysis, the size-based SUV<sub>max</sub> cutoff values were 1.9, 2.5, and 3.0 for lymph nodes <10 mm, 10–15 mm, and >15 mm, respectively. These cutoff values yielded 79% sensitivity and 99% specificity for nodal-level staging.<sup>29</sup>

False-negative results are found in nodes that are small, necrotic, and metabolically less active and in those nodes that cannot be separated anatomically from the primary tumor. False-positive results are commonly due to reactive nodes. For this reason, usually tissue diagnosis is necessary in FDG-positive nodes, in which suspected metastatic involvement would significantly alter management or prognosis.

### M Stage


One of the important benefits of PET/DCT is its ability to image the body routinely from the skull base to midhigh. PET/DCT detects not only the locoregional nodal metastasis but distant nodal and organ metastases. The incidence of distant metastases from HNSCC is between approximately 10% and 25%, and metastases are commonly found in the lungs (most common site), mediastinal nodes, bone, and liver. PET/DCT is extremely valuable in identifying the distant metastasis and second primary malignancies in patients with HNSCC.<sup>30–32</sup>

### Radiation-Therapy Planning

With the increasing use of conformal radiation therapy and IMRT in the treatment of locally advanced head and neck cancer, target-volume definition has become of paramount importance. With conventional CT scanning with or without contrast, delineating the GTV is often difficult because there may not be a clear demarcation between tumor and normal tissue. Combining PET with CT is useful in aiding GTV contouring because the metabolic activity of the tumor demarcates the boundary between active tumor and normal surrounding tissue (Fig 6). By accurate GTV definition with the assistance of PET/CT, smaller expansions may potentially be used to create clinical target volumes and subsequent PTV, which are used as a basis for IMRT planning and creating optimal radiation-dose coverage of the tumor.

Fusion of a diagnostic PET scan or PET/CT to the radiation planning CT scan can be plagued with positional variations between the 2 scans if they are obtained at 2 different times. This may be overcome by deformable registration software or by fusing the 2 image sets by using anatomic landmarks that closely correspond with the tumor location. In our institution, a dedicated radiation therapy planning PET/CT is done. This dedicated PET/CT radiation planning scan is obtained in the customary head and neck immobilization device used for the radiation treatments by using a carbon fiber resin bed. This allows accurate positioning of both image sets because the images are acquired at the same time points and in the same positions.<sup>33</sup> By accurately defining the GTV with FDG-PET/CT or other potential functional imaging tools such as <sup>18</sup>F-labeled fluoroisonidazole PET/CT, there may be future applications for dose escalation of the GTV to deliver greater tumoricidal doses, while still maintaining adjacent normal tissue within radiation tolerance.<sup>34</sup>

The use of PET/CT scanning in radiation planning and contour definition may, however, potentially underestimate tumor volume definition if areas of the tumor demonstrate necrosis or lack of metabolic activity. Thus, it is important to



**Fig 7.** Therapy assessment, complete response. A 39-year-old male patient with a stage IVa (T4N3M0) SCC of the right tonsil who underwent induction chemotherapy. A postinduction therapy PET/DCT demonstrates complete metabolic resolution of the primary tumor and nodal metastases. A and E, Maximum intensity projection views. B–D and F–H, Fused PET/CT images.

integrate diagnostic information, including contrast-enhanced CT of a PET/DCT or MR imaging, and clinical examination findings into a target definition for radiation planning and not to rely only on 1 imaging tool. In a series by Ford et al,<sup>35</sup> tumor-boundary delineation by using PET was investigated and uncertainties in tumor-boundary delineation were studied as a function of the reconstruction method. The series found that PET-based contours were a sensitive function of threshold contouring level and that a 5% change in threshold contour level could translate into a 200% increase in volume. Hence, there still remains the potential for uncertainty of the tumor-delineation boundary by using PET imaging for radiation planning, and our knowledge of the application of PET/CT to radiation planning for head and neck cancer will continue to evolve as additional studies become available.

### Evaluation of Therapy Response

Surgery and radiation therapy produce edema, hyperemia, fibrosis, and loss of tissue facial planes. Differentiation of residual or recurrent tumors from posttherapeutic changes by anatomic imaging with CT or MR imaging can be difficult. Some new therapies may be cytostatic instead of cytoreductive, in which successful treatments may not lead to a decrease in tumor size. Posttherapeutic changes, including scar tissue, which mimic residual or recurrent tumors on anatomic imaging, would demonstrate no metabolic activity on PET imaging.

FDG-PET detects tumor metabolic changes as a response to therapy. The FDG findings in posttherapy examinations should be therapy- and time-specific. Surgery or chemoradiation or both are the mainstays of treatment for head and neck malignancy. Increased FDG uptake will be seen in recently irradiated tissues and appears to be more intense in tissues that receive the highest radiation. Radiation-related FDG hypermetabolism may last  $\geq 12$ –16 months after therapy.<sup>36</sup> There is overlap in the SUVs of radiation-related FDG uptake and tumor recurrence, which may pose a problem for interpretation, especially if the PET/CT is performed within 2 months of therapy. PET/CT is more accurate when performed at 3–4 months after the completion of radiation therapy than at earlier time points,<sup>37–39</sup> likely due to reduction in the nonspecific inflam-


matory uptake. PET/CT had a higher specificity for detecting persistent tumor after radiation therapy than contrast CT alone, and the specificity of PET/CT was highest when it was performed after 8 weeks of treatment.<sup>30</sup> In our institution, we perform posttherapy PET/CT at least 8 weeks after completion of radiation therapy. FDG hypermetabolism associated with chemotherapy-related inflammation is a minimal problem compared with radiation-induced inflammatory uptake and usually subsides to normal within a week. In our institution, we image the patients just before the next cycle of chemotherapy to assess therapy response.

A number of studies have shown that PET can detect residual tumor after chemoradiation more accurately than conventional imaging.<sup>37,40–42</sup> However, due to inflammatory uptake, a positive PET/CT result in the head and neck must be correlated with the physical examination and a tissue biopsy may be warranted.

A greater potential impact of FDG-PET is its ability to exclude disease, thereby avoiding the further investigation or more extensive local or systemic treatment. Many studies have demonstrated the very high negative predictive value of PET/CT in posttherapy assessment of head and neck malignancy (Fig 7).<sup>30,37,38,43–46</sup> Porceddu et al<sup>38</sup> demonstrated that a negative PET/CT result is highly reliable when PET/CT is performed at least 2–3 months after the completion of therapy. In this study, 39 eligible patients who had a residual mass in the head and neck underwent PET scanning at a median of 12 weeks (range, 8–32 weeks) after therapy. PET showed no metabolic activity in these patients. Five of these patients had neck dissections, which were all pathologically negative. The remaining 27 patients were observed for a median of 34 months (range, 16–86 months), with only 1 locoregional failure. The negative predictive value of PET for viable disease in a residual anatomic abnormality was 97%. When a posttherapy FDG-PET/CT demonstrates residual uptake, it requires tissue diagnosis and possible salvage surgery (Fig 8).

### Evaluation of Recurrence and Surveillance

All patients with HNSCC are at high risk for tumor recurrence and development of a second primary tumor in the aerodigestive tract. Tumor subsite, the stage of tumor at presentation,



**Fig 8.** Therapy assessment, partial response. A 67-year-old male patient with a history of recurrent SCC of the oral tongue, SCC of the midesophagus, and SCC of the left soft palate (T2N0M0) status postresection with negative margins, who presented with a recurrent left neck mass. The pretherapy PET/CT demonstrates FDG hypermetabolic left level I nodal recurrence (red arrow), and the patient completed chemoradiotherapy to the recurrent tumor in his left neck with IMRT to a dose of 70 Gy. A 12-week posttherapy PET/DCT scan demonstrates residual activity (gold arrow) in the periphery and central necrosis of the left neck nodal mass, representing partial response and a new recurrence of the esophageal malignancy (green arrow).

nerve invasion, extracapsular lymph node spread, and positive margins predict a higher risk of tumor recurrence. Persistent smoking and alcohol consumption are ongoing risk factors. The only meaningful way to detect possible recurrence by anatomic modalities such as CT and MR imaging is by change in size or possible contrast-enhancement of an abnormal area. The superiority of PET to anatomic imaging modalities for identifying local and regional recurrence of head and neck cancer after therapy has been demonstrated in a number of studies.<sup>19,37,44,47-50</sup> Lowe et al<sup>49</sup> performed a prospective study of 44 patients with stage III or IV head and neck cancer with serial posttherapy FDG-PET studies. PET was performed twice during the first posttreatment year (at 2 and 10 months after therapy) and thereafter as needed. After therapy, patients were grouped on the basis of tissue biopsies into those who achieved a CR and those who had RD. Patients who achieved a CR were further grouped into those without evidence of disease and those who had recurrence by 1 year after completion of therapy. Disease status as determined by physical examination, PET, and correlative imaging was compared. Eight patients were lost to follow-up, and 6 had RD after therapy. Of the remaining 30 patients with a CR, 16 had recurrence in the first year after therapy. Five of these 16 patients had recurrence detected by PET only; 4, by PET and correlative imaging only; 5, by physical examination and PET only; and 2, by physical examination, correlative imaging, and PET. Only PET detected all recurrences in the first year, and it performed better than correlative imaging ( $P = .013$ ) or physical examination ( $P = .002$ ) in the detection of recurrence.

We concluded that PET can detect head and neck tumor recurrence when it may be undetectable by other clinical methods and FDG-PET permits highly accurate detection of head and neck cancer recurrence in the posttherapy period.<sup>49</sup> Anzai et al<sup>47</sup> used receiver operator characteristic analysis to compare PET and CT/MR imaging in patients presenting symptoms suggesting recurrence and no obvious tumor mass. PET demonstrated higher sensitivity and specificity with a significant difference in the area under the curve.<sup>47</sup> PET detected twice as many recurrences compared with physical examination and CT in routine surveillance of patients who had completed treatment for head and neck cancer.<sup>50</sup>

In the setting of surveillance, numerous studies have dem-

onstrated that <sup>18</sup>F-FDG-PET/CT has a relatively high sensitivity for detecting recurrent disease at the primary tumor site and regional lymph node metastases.<sup>37,38-45,49-52</sup> For patients who underwent PET or PET/CT at least 12 weeks after the completion of all therapy, the reported sensitivity ranged between 90% and 100% for the detection of recurrence. Due to nonspecific inflammatory uptake, the specificity of PET and PET/CT is between 63% and 94%, and a tissue biopsy or short-interval repeat scanning is warranted. If initial biopsy findings at the site of a PET abnormality are negative, a repeat biopsy or close follow-up with PET/CT should be undertaken to minimize biopsy sampling errors.

Some studies have suggested that FDG-PET does not appear to be sufficiently sensitive (40%–75%) or specific (25%–64%) in identifying the presence of micrometastases in cervical nodes after completion of chemotherapy.<sup>43,53</sup> However, a recent study demonstrated a sensitivity, specificity, positive predictive value, and negative predictive value of 100%, 84.2%, 62.5%, and 100%, respectively, by using an  $SUV_{max} < 3.0$  as the criterion for negative findings on FDG-PET.<sup>52</sup> In this study, 24 hemi-necks in 23 patients with residual lymphadenopathy underwent neck dissection or FNA. The pathology correlated strongly with the postradiotherapy FDG-PET studies. All patients with negative finding on postradiotherapy FDG-PET and those with an  $SUV_{max}$  of  $< 3.0$  on the postradiotherapy FDG-PET were found to be free from residual viable tumor.

There are no evidence-based recommendations for the frequency of surveillance of PET/CT studies in the management of head and neck cancer. In our institution, we recommend a surveillance PET/DCT every 6 months for 2 years from primary therapy and thereafter every 12 months for another 3 years.

In summary, PET/DCT is useful for identification of an unknown primary tumor, delineation of extent of primary tumor, regional lymph node involvement, distant metastases, and occasional synchronous primary tumor, assessing therapy response, and long-term surveillance for recurrence and metastases. The role of PET/CT is evolving in radiation therapy planning. Combined PET/DCT provides the best anatomic and metabolic in vivo information for the comprehensive management of patients with head and neck cancer.

## References

1. Carvalho A, Nishimoto I, Califano J, et al. Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. *Int J Cancer* 2005;114:806–16
2. Canto MT, Devesa SS. Oral cavity and pharynx cancer incidence rates in the United States, 1975–1998. *Oral Oncol* 2002;38:610–17
3. Forastiere A, Koch W, Trotti A, et al. Head and neck cancer. *N Engl J Med* 2001;345:1890–900
4. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. *N Engl J Med* 2004;350:1937–44
5. Bernier J, Dommene C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. *N Engl J Med* 2004;350:1945–52
6. Whitehurst J, Droulias C. Surgical treatment of squamous cell carcinoma of the oral tongue: factors influencing survival. *Arch Otolaryngol* 1977;103:212–15
7. Snow G, Annyas A, van Slooten E, et al. Prognostic factors of neck node metastases. *Clin Otolaryngol* 1982;7:185–92
8. Czernin J, Schelbert H. PET/CT imaging: facts, opinions, hopes, and questions. *J Nucl Med* 2004;45:S1–S5
9. Beyer T, Antoch G, Muller S, et al. Acquisition protocol considerations for combined PET/CT imaging. *J Nucl Med* 2004;45:25S–35S
10. Wong T, Paulson E, Nelson R, et al. Practical approach to diagnostic CT combined with PET. *AJR Am J Roentgenol* 2007;188:622–29
11. Kole A, Nieweg O, Pruijm J, et al. Detection of unknown occult primary tumors using positron emission tomography. *Cancer* 1998;82:1160–66
12. Johansen J, Eigtved A, Buchwald C, et al. Implication of 18F-fluoro-2-deoxy-D-glucose positron emission tomography on management of carcinoma of unknown primary in the head and neck: a Danish cohort study. *Laryngoscope* 2002;112:2009–14
13. Jungehulsing M, Scheidhauer K, Damm M, et al. 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography is a sensitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with head and neck lymph node manifestation. *Otolaryngol Head Neck Surg* 2000;123:294–301
14. Aassar OS, Fischbein NJ, Caputo GR, et al. Metastatic head and neck cancer: role and usefulness of FDG PET in locating occult primary tumors. *Radiology* 1999;210:177–81
15. Rusthoven K, Koshy M, Paulino A. The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor. *Cancer* 2004;101:2641–49
16. Johansen J, Buus S, Loft A, et al. Prospective study of 18FDG-PET in the detection and management of patients with lymph node metastases to the neck from an unknown primary tumor: results from the DAHANCA-13 study. *Head Neck* 2008;30:471–78
17. Nassenstein K, Veit-Haibach P, Stergar H, et al. Cervical lymph node metastases of unknown origin: primary tumor detection with whole-body positron emission tomography/computed tomography. *Acta Radiol* 2007 Oct 23:1–8 [Epub ahead of print]
18. Miller F, Karnad A, Eng T, et al. Management of the unknown primary carcinoma: long-term follow-up on a negative PET scan and negative panendoscopy. *Head Neck* 2008;30:28–34
19. Wong W, Chevretton E, McGurk M, et al. A prospective study of PET-FDG imaging for the assessment of head and neck squamous cell carcinoma. *Clin Otolaryngol Allied Sci* 1997;22:209–14
20. Ha P, Hdeib A, Goldenberg D, et al. The role of positron emission tomography and computed tomography fusion in the management of early-stage and advanced-stage primary head and neck squamous cell carcinoma. *Arch Otolaryngol Head Neck Surg* 2006;132:12–16
21. Layland M, Sessions D, Lenox J. The influence of lymph node metastasis in the treatment of squamous cell carcinoma of the oral cavity, oropharynx, larynx, and hypopharynx: N0 versus N+. *Laryngoscope* 2005;115:629–39
22. Curtin H, Ishwaran H, Mancuso A, et al. Comparison of CT and MR imaging in staging of neck metastases. *Radiology* 1998;207:123–30
23. van den Brekel M, Stel H, Castelijn J, et al. Cervical lymph node metastasis: assessment of radiologic criteria. *Radiology* 1990;177:379–84
24. Sakai O, Curtin H, Romo L, et al. Lymph node pathology: benign proliferative, lymphoma, and metastatic disease. *Radiol Clin North Am* 2000;38:979–98
25. Schmid D, Stoeckli S, Bandhauer F, et al. Impact of positron emission tomography on the initial staging and therapy in locoregional advanced squamous cell carcinoma of the head and neck. *Laryngoscope* 2003;113:888–91
26. Schwartz D, Rajendran J, Yueh B, et al. Staging of head and neck squamous cell cancer with extended-field FDG-PET. *Arch Otolaryngol Head Neck Surg* 2003;129:1173–78
27. Schoder H, Yeung H. Positron emission imaging of head and neck cancer, including thyroid carcinoma. *Semin Nucl Med* 2004;34:180–97
28. Braams J, Pruijm J, Freling N, et al. Detection of lymph node metastases of squamous-cell cancer of the head and neck with FDG-PET and MRI. *J Nucl Med* 1995;36:211–16
29. Murakami R, Uozumi H, Hirai T, et al. Impact of FDG-PET/CT imaging on nodal staging for head-and-neck squamous cell carcinoma. *Int J Radiat Oncol Biol Phys* 2007;68:377–82. Epub 2007 Feb 22
30. Ryan W, Fee WJ, Le Q, et al. Positron-emission tomography for surveillance of head and neck cancer. *Laryngoscope* 2005;115:645–50
31. Manolidis S, Donald P, Volk P, et al. The use of positron emission tomography scanning in occult and recurrent head and neck cancer. *Acta Otolaryngol Suppl* 1998;534:1–11
32. Brouwer J, Senft A, de Bree R, et al. Screening for distant metastases in patients with head and neck cancer: is there a role for (18)FDG-PET? *Oral Oncol* 2006;42:275–80
33. Vogel W, Schinagl D, Van Dalen J, et al. Validated image fusion of dedicated PET and CT for external beam radiation and therapy in the head and neck area. *Q J Nucl Med Mol Imaging* 2008;2008:74–83
34. Lee NY, Mechalakos JG, Nehmeh S, et al. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study. *Int J Radiat Oncol Biol Phys* 2008;70:2–13. Epub 2007 Sep 14
35. Ford E, Kinahan P, Hanlon L, et al. Tumor delineation using PET in head and neck cancers: threshold contouring and lesion volumes. *Med Phys* 2006;33:4280–88
36. Lowe V, Hebert M, Anscher M, et al. Serial evaluation of increased chest wall F-18 fluorodeoxyglucose (FDG) uptake following radiation therapy in patients with bronchogenic carcinoma. *Clin Positron Imaging* 1998;1:185–91
37. Andrade RS, Heron DE, Degirmenci B, et al. Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers. *Int J Radiat Oncol Biol Phys* 2006;65:1315–22
38. Porceddu S, Jarmolowski E, Hicks R, et al. Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer. *Head Neck* 2005;27:175–81
39. Quon A, Fischbein NJ, McDougall IR, et al. Clinical role of 18F-FDG PET/CT in the management of squamous cell carcinoma of the head and neck and thyroid carcinoma. *J Nucl Med* 2007;48:58S–67S
40. Kitagawa Y, Nishizawa S, Sano K, et al. Prospective comparison of 18F-FDG PET with conventional imaging modalities (MRI, CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma. *J Nucl Med* 2003;44:198–206
41. Goerres GW, Schmid DT, Bandhauer F, et al. Positron emission tomography in the early follow-up of advanced head and neck cancer. *Arch Otolaryngol Head Neck Surg* 2004;130:105–09
42. Klabbers BM, Lammertsma AA, Slotman BJ. The value of positron emission tomography for monitoring response to radiotherapy in head and neck cancer. *Mol Imaging Biol* 2003;5:257–70
43. Brkovich V, Miller F, Karnad A, et al. The role of positron emission tomography scans in the management of the N-positive neck in head and neck squamous cell carcinoma after chemoradiotherapy. *Laryngoscope* 2006;116:855–58
44. Kubota K, Yokoyama J, Yamaguchi K, et al. FDG-PET delayed imaging for the detection of head and neck cancer recurrence after radio-chemotherapy: comparison with MRI/CT. *Eur J Nucl Med Mol Imaging* 2004;31:590–95
45. Yao M, Graham MM, Hoffman HT, et al. The role of post-radiation therapy FDG PET in prediction of necessity for post-radiation therapy neck dissection in locally advanced head-and-neck squamous cell carcinoma. *Int J Radiat Oncol Biol Phys* 2004;59:1001–10
46. Yao M, Buatti JM, Dornfeld KJ, et al. Can post-RT FDG PET accurately predict the pathologic status in neck dissection after radiation for locally advanced head and neck cancer? In regard to Rogers, et al. (*Int J Radiat Oncol Biol Phys* 2004;58:694–97). *Int J Radiat Oncol Biol Phys* 2005;61:306–07, author reply 307
47. Anzai Y, Carroll WR, Quint DJ, et al. Recurrence of head and neck cancer after surgery or irradiation: prospective comparison of 2-deoxy-2-[F-18]fluoro-D-glucose PET and MR imaging diagnoses. *Radiology* 1996;200:135–41
48. Kao CH, ChangLai SP, Chieng PU, et al. Detection of recurrent or persistent nasopharyngeal carcinomas after radiotherapy with 18-fluoro-2-deoxyglucose positron emission tomography and comparison with computed tomography. *J Clin Oncol* 1998;16:3550–55
49. Lowe VJ, Boyd JH, Dunphy FR, et al. Surveillance for recurrent head and neck cancer using positron emission tomography. *J Clin Oncol* 2000;18:651–58
50. Fischbein NJ, Aassar OS, Caputo GR, et al. Clinical utility of positron emission tomography with 18F-fluorodeoxyglucose in detecting residual/recurrent squamous cell carcinoma of the head and neck. *AJNR Am J Neuroradiol* 1998;19:1189–96
51. Wong RJ, Lin DT, Schoder H, et al. Diagnostic and prognostic value of [18F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. *J Clin Oncol* 2002;20:4199–208
52. Yao M, Luo P, Hoffman H, et al. Pathology and FDG PET correlation of residual lymph nodes in head and neck cancer after radiation treatment. *Am J Clin Oncol* 2007;30:264–70
53. Gourin C, Williams H, Seabolt W, et al. Utility of positron emission tomography-computed tomography in identification of residual nodal disease after chemoradiation for advanced head and neck cancer. *Laryngoscope* 2006;116:705–10